CAS No. :	1029712-80-8
Formula :	C₂₃H₁₇FN₆O
M.W :	412.42
SMILES Code :	O=C(NC)C1=CC=C(C2=NN3C(N=C2)=NC=C3CC4=CC=C5N=CC=CC5=C4)C=C1F
Synonyms :	INCB28060; INC280; NVP-INC280
MDL No. :	MFCD18633285
InChI Key :	LIOLIMKSCNQPLV-UHFFFAOYSA-N
Pubchem ID :	25145656

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

WT and Tpl2−/−keratinocytes	0.1 nM	2 h	Capmatinib inhibited the HGF-stimulated p-MET and fully blocked the HGF-mediated increase in p-EGFR, restoring levels to baseline conditions.	Oncogenesis. 2019 Jan 10;8(1):1.
NF1-MET and NF1-P53 cells	100 nM	72 h	To evaluate the sensitivity of NF1-MET and NF1-P53 cells to Capmatinib, the results showed that NF1-P53 cells were resistant to Capmatinib and Trametinib as single agents and in combination therapy.	Oncogene. 2024 May;43(19):1411-1430.
PC3M cells	10 nM	24 h	To evaluate the effect of Capmatinib on the migration and invasion capacity of PC3M cells. Results showed that Capmatinib significantly reduced the migratory capacity of cells.	Mol Oncol. 2025 Feb;19(2):474-495.
PC3 cells	10 nM	24 h	To evaluate the effect of Capmatinib on the migration and invasion capacity of PC3 cells. Results showed that Capmatinib significantly reduced the migratory capacity of cells.	Mol Oncol. 2025 Feb;19(2):474-495.
EBC-1	1.5, 2.2, 2.4 μM	2 months	To establish capmatinib-resistant NSCLC cell lines and evaluate their resistance mechanisms. Results showed that capmatinib-resistant NSCLC cells were dependent on alternative pathway activation.	Cancer Res Treat. 2019 Jul;51(3):951-962.

BALB/C nude mice	Orthotopic metastatic model	Oral	10 mg/kg	Once daily for 8 weeks	To evaluate the inhibitory effect of Capmatinib combined with Defactinib on ETV1-induced HCC metastasis.	J Exp Clin Cancer Res. 2022 Sep 16;41(1):275
Mice	Tpl2−/−mice	Dietary administration	44 mg/kg	Continued for 52 weeks	Capmatinib treatment significantly reduced the overall tumor burden in Tpl2?/?mice and prevented all malignant conversion of benign papillomas to invasive SCC.	Oncogenesis. 2019 Jan 10;8(1):1.
Mice	MPNST xenograft model	Oral	30 mg/kg	Twice daily for 15 days	To evaluate the impact of p53 loss on Capmatinib sensitivity, the results showed that Capmatinib significantly inhibited tumor growth in both NF1-MET and NF1-MET;sgP53 models, but only NF1-MET tumors regressed during treatment, while NF1-MET;sgP53 tumors remained stable, with a subset of tumors showing increased growth.	Oncogene. 2024 May;43(19):1411-1430.
Mice	NSG-hHGFki mice	Oral	10 mg/kg	5 days a week for 4 weeks	To evaluate the effect of Capmatinib on tumour growth in NSG-hHGFki mice. Results showed that Capmatinib significantly reduced the tumour volume induced by ETV1 and ERG overexpressing cells.	Mol Oncol. 2025 Feb;19(2):474-495.
Mice	Hepa1-6, HCA-1 and DEN HCC models	Oral	10 mg/kg	Once daily for 5 days	The combination of Capmatinib with PD-1 blockade significantly enhanced antitumor efficacy in HCC models, particularly in the αPD-1 refractory DEN model, outperforming the type II inhibitor Cabozantinib.	J Immunother Cancer. 2024 Oct 30;12(10):e009690

NCT03693339	Cancer\|Lung Cancer Metastatic\|... More >>MET Gene Mutation Less <<	PHASE2	UNKNOWN	2022-06-30	Asan Medical Center, Seoul, 05... More >>505, Korea, Republic of Less <<
NCT05567055	Non-small Cell Lung Cancer	PHASE2	WITHDRAWN	2025-09-28	-
NCT02019693	Kidney Cancer	PHASE2	COMPLETED	2021-12-17	National Institutes of Health ... More >>Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States Less <<
NCT02414139	Carcinoma, Non-Small-Cell Lung	PHASE2	COMPLETED	2023-05-16	Pacific Shores Medical Group S... More >>C, Long Beach, California, 90813, United States\|University Of California Los Angeles Dept of Onc, Los Angeles, California, 90095, United States\|University of California Irvine Medical Center Chao Family Chao Family Comp Cancer Center, Orange, California, 92868, United States\|H Lee Moffitt Cancer Center and Research Institute ., Tampa, Florida, 33612, United States\|University of Iowa Hospitals and Clinics SC-3, Iowa City, Iowa, 52242, United States\|Massachusetts General Hospital MGH Cancer Center, Boston, Massachusetts, 02114, United States\|VA Ann Arbor Health System VA Ann Arbor Health System, Ann Arbor, Michigan, 48105, United States\|Mayo Clinic Rochester ., Rochester, Minnesota, 55905, United States\|Oregon Health and Science University SC, Portland, Oregon, 97239, United States\|Lehigh Valley Health Network SC, Allentown, Pennsylvania, 18103, United States\|Andrew and Patel Associates, Camp Hill, Pennsylvania, 17011, United States\|Mays Cancer Ctr Uthsa Mdacc SC-5, San Antonio, Texas, 78229, United States\|University of Utah / Huntsman Cancer Institute Oncology, Salt Lake City, Utah, 84103, United States\|Novartis Investigative Site, Caba, Buenos Aires, C1426ANZ, Argentina\|Novartis Investigative Site, Buenos Aires, Caba, C1431FWO, Argentina\|Novartis Investigative Site, La Rioja, 5300, Argentina\|Novartis Investigative Site, Wien, 1210, Austria\|Novartis Investigative Site, Leuven, 3000, Belgium\|Novartis Investigative Site, Marseille cedex 20, Bouches Du Rhone, 13915, France\|Novartis Investigative Site, Dijon, Cote D Or, 21034, France\|Novartis Investigative Site, Clermont-Ferrand, 63011, France\|Novartis Investigative Site, La Tronche, 38700, France\|Novartis Investigative Site, Lille, 59000, France\|Novartis Investigative Site, Marseille, 13273, France\|Novartis Investigative Site, Paris, 75970, France\|Novartis Investigative Site, Pierre Benite, 69495, France\|Novartis Investigative Site, Rennes, 35043, France\|Novartis Investigative Site, Strasbourg Cedex, 67091, France\|Novartis Investigative Site, Heidelberg, Baden-Württemberg, 69126, Germany\|Novartis Investigative Site, Berlin, 13125, Germany\|Novartis Investigative Site, Frankfurt, 60590, Germany\|Novartis Investigative Site, Gottingen, 37075, Germany\|Novartis Investigative Site, Halle (Saale), 06120, Germany\|Novartis Investigative Site, Hamburg, 20251, Germany\|Novartis Investigative Site, Hannover, 30625, Germany\|Novartis Investigative Site, Homburg, 66421, Germany\|Novartis Investigative Site, Koeln, 50937, Germany\|Novartis Investigative Site, Muenchen, 81925, Germany\|Novartis Investigative Site, Nuernberg, 90419, Germany\|Novartis Investigative Site, Ravensburg, 88214, Germany\|Novartis Investigative Site, Tuebingen, 72076, Germany\|Novartis Investigative Site, Ulm, 89081, Germany\|Novartis Investigative Site, Ramat Gan, 52621, Israel\|Novartis Investigative Site, Tel Aviv, 6423906, Israel\|Novartis Investigative Site, Bologna, BO, 40138, Italy\|Novartis Investigative Site, Brescia, BS, 25123, Italy\|Novartis Investigative Site, Catania, CT, 95124, Italy\|Novartis Investigative Site, Catanzaro, CZ, 88100, Italy\|Novartis Investigative Site, Meldola, FC, 47014, Italy\|Novartis Investigative Site, Firenze, FI, 50134, Italy\|Novartis Investigative Site, Monza, MB, 20900, Italy\|Novartis Investigative Site, Milano, MI, 20141, Italy\|Novartis Investigative Site, Milano, MI, 20162, Italy\|Novartis Investigative Site, Modena, MO, 41124, Italy\|Novartis Investigative Site, Roma, RM, 00155, Italy\|Novartis Investigative Site, Verona, VR, 37126, Italy\|Novartis Investigative Site, Napoli, 80131, Italy\|Novartis Investigative Site, Nagoya, Aichi, 464 8681, Japan\|Novartis Investigative Site, Nagoya, Aichi, 466 8560, Japan\|Novartis Investigative Site, Fukuoka-city, Fukuoka, 811-1395, Japan\|Novartis Investigative Site, Akashi, Hyogo, 673-8558, Japan\|Novartis Investigative Site, Sendai city, Miyagi, 980 0873, Japan\|Novartis Investigative Site, Okayama-city, Okayama, 700-8558, Japan\|Novartis Investigative Site, Osaka Sayama, Osaka, 589 8511, Japan\|Novartis Investigative Site, Chuo ku, Tokyo, 104 0045, Japan\|Novartis Investigative Site, Koto ku, Tokyo, 135 8550, Japan\|Novartis Investigative Site, Ube-city, Yamaguchi, 755-0241, Japan\|Novartis Investigative Site, Bundang Gu, Gyeonggi Do, 13620, Korea, Republic of\|Novartis Investigative Site, Gyeonggi do, Korea, 10408, Korea, Republic of\|Novartis Investigative Site, Seoul, 03080, Korea, Republic of\|Novartis Investigative Site, Ashrafieh, 166830, Lebanon\|Novartis Investigative Site, Mexico, Distrito Federal, 14080, Mexico\|Novartis Investigative Site, Amsterdam, 1066 CX, Netherlands\|Novartis Investigative Site, Groningen, 9713 GZ, Netherlands\|Novartis Investigative Site, Maastricht, 6229 HX, Netherlands\|Novartis Investigative Site, Rotterdam, 3015 GD, Netherlands\|Novartis Investigative Site, Oslo, NO 0424, Norway\|Novartis Investigative Site, Moscow, 109028, Russian Federation\|Novartis Investigative Site, Saint Petersburg, 192148, Russian Federation\|Novartis Investigative Site, Tambov, 392000, Russian Federation\|Novartis Investigative Site, Singapore, 119228, Singapore\|Novartis Investigative Site, Singapore, 168583, Singapore\|Novartis Investigative Site, Sevilla, Andalucia, 41009, Spain\|Novartis Investigative Site, Oviedo, Asturias, 33011, Spain\|Novartis Investigative Site, Barcelona, Catalunya, 08035, Spain\|Novartis Investigative Site, Barcelona, Catalunya, 08036, Spain\|Novartis Investigative Site, La Coruna, Galicia, 15006, Spain\|Novartis Investigative Site, Madrid, 28034, Spain\|Novartis Investigative Site, Madrid, 28041, Spain\|Novartis Investigative Site, Stockholm, SE-171 76, Sweden\|Novartis Investigative Site, Kaohsiung, 82445, Taiwan\|Novartis Investigative Site, Taipei, 10002, Taiwan\|Novartis Investigative Site, Taoyuan, 33305, Taiwan\|Novartis Investigative Site, Birmingham, B9 5SS, United Kingdom\|Novartis Investigative Site, London, W6 8RF, United Kingdom Less <<
NCT02474537	Hepatic Impairment	PHASE1	COMPLETED	2017-09-12	University of Miami Miller Sch... More >>ool of Medicine Clinical Resea Oncology, Miami, Florida, 33136, United States\|Clinical Pharmacology of Miami, LLC., Miami, Florida, 33142, United States\|Orlando Clinical Research Center, Orlando, Florida, 32086, United States\|DaVita Clinical Research, Minneapolis, Minnesota, 55404, United States\|Duke University Medical Center Oncology, Durham, North Carolina, 27710, United States Less <<
NCT01546428	Advanced Solid Tumor	PHASE1	COMPLETED	2025-01-16	Novartis Investigative Site, K... More >>ashiwa, Chiba, 277-8577, Japan\|Novartis Investigative Site, Fukuoka, 811-1395, Japan Less <<
NCT05154344	MET Alterations\|Non Small Cell... More >> Lung Cancer\|METex14 Mutations Less <<		COMPLETED	2022-02-01	CHU, Lille, France\|CHU, Tours,... More >> France Less <<
NCT01737827	Advanced Hepatocellular Carcin... More >>oma With c-MET Dysregulation Less <<	PHASE2	TERMINATED	2023-05-24	Novartis Investigative Site, N... More >>anjing, Jiangsu, 210002, China\|Novartis Investigative Site, Xi'an, Shanxi, 710032, China\|Novartis Investigative Site, Hangzhou, Zhejiang, 310016, China\|Novartis Investigative Site, Hong Kong, Hong Kong\|Novartis Investigative Site, Singapore, 168583, Singapore\|Novartis Investigative Site, Khon Kaen, THA, 40002, Thailand\|Novartis Investigative Site, Bangkok, 10330, Thailand\|Novartis Investigative Site, Bangkok, 10700, Thailand Less <<
NCT05675683	Metastatic Non-Small Cell Lung... More >> Cancer Less <<		COMPLETED	2021-12-31	18 Novartis Investigative Site... More >>s in the US, East Hanover, New Jersey, 07936-1080, United States Less <<
NCT03240393	Carcinoma\|Non-Small-Cell Lung ... More >>Cancer Less <<	PHASE2	WITHDRAWN	2021-10-26	-
NCT02925104	cMET Dysegulation Advanced Sol... More >>id Tumors Less <<	PHASE1	COMPLETED	2018-05-16	Indiana University Simon Cance... More >>r Center SC, Indianapolis, Indiana, 46202, United States\|Novartis Investigative Site, Salzburg, 5020, Austria\|Novartis Investigative Site, Herlev, 2730, Denmark\|Novartis Investigative Site, Dresden, 01307, Germany\|Novartis Investigative Site, Mainz, 55131, Germany\|Novartis Investigative Site, Nijmegen, 6500 HB, Netherlands\|Novartis Investigative Site, Malaga, Andalucia, 29010, Spain\|Novartis Investigative Site, Santiago de Compostela, Galicia, 15706, Spain\|Novartis Investigative Site, Barcelona, 08041, Spain\|Novartis Investigative Site, Madrid, 28040, Spain\|Novartis Investigative Site, Zaragoza, 50009, Spain\|Novartis Investigative Site, Goteborg, 413 45, Sweden\|Novartis Investigative Site, Lund, SE-221 85, Sweden\|Novartis Investigative Site, Stockholm, 171 76, Sweden\|Novartis Investigative Site, Uppsala, SE-751 85, Sweden\|Novartis Investigative Site, London, W1G 6AD, United Kingdom\|Novartis Investigative Site, Manchester, M20 4BX, United Kingdom Less <<
NCT04741789	Carcinoma, Non-Small Cell Lung... More >>\|Non-Small Cell Lung Cancer\|Non-Small-Cell Lung Carcinoma\|Nonsmall Cell Lung Cancer Less <<		AVAILABLE	-	-
NCT01324479	Solid Tumors	PHASE1	COMPLETED	2017-07-04	Highlands Oncology Group, Faye... More >>tteville, Arkansas, 72703, United States\|University of Chicago SC, Chicago, Illinois, 60637, United States\|Karmanos Cancer Institute Wayne St Karmanos, Detroit, Michigan, 48201, United States\|Sarah Cannon Research Institute Dept of Onc, Nashville, Tennessee, 37203, United States\|University of Texas/MD Anderson Cancer Center Dept of Onc, Houston, Texas, 77030-4009, United States\|Novartis Investigative Site, Westmead, New South Wales, 2145, Australia\|Novartis Investigative Site, Woolloongabba, Queensland, 4102, Australia\|Novartis Investigative Site, Ottawa, Ontario, K1H 8L6, Canada\|Novartis Investigative Site, Toronto, Ontario, M5G 2M9, Canada\|Novartis Investigative Site, La Tronche, 38700, France\|Novartis Investigative Site, LILLE Cédex, 59037, France\|Novartis Investigative Site, Strasbourg Cedex, 67091, France\|Novartis Investigative Site, Essen, 45147, Germany\|Novartis Investigative Site, Frankfurt, 60590, Germany\|Novartis Investigative Site, Freiburg, 79106, Germany\|Novartis Investigative Site, Gottingen, 37075, Germany\|Novartis Investigative Site, Hannover, 30625, Germany\|Novartis Investigative Site, Oldenburg, 26121, Germany\|Novartis Investigative Site, Hong Kong, Hong Kong\|Novartis Investigative Site, Shatin, New Territories, Hong Kong\|Novartis Investigative Site, Haifa, 3525408, Israel\|Novartis Investigative Site, Kfar Saba, 4428164, Israel\|Novartis Investigative Site, Ramat Gan, 5265601, Israel\|Novartis Investigative Site, Tel Aviv, 6423906, Israel\|Novartis Investigative Site, Ancona, AN, 60126, Italy\|Novartis Investigative Site, Meldola, FC, 47014, Italy\|Novartis Investigative Site, Milano, MI, 20133, Italy\|Novartis Investigative Site, Milano, MI, 20162, Italy\|Novartis Investigative Site, Reggio Emilia, RE, 42123, Italy\|Novartis Investigative Site, Seoul, Gyeonggi Do, 03080, Korea, Republic of\|Novartis Investigative Site, Gyeonggi do, Korea, 10408, Korea, Republic of\|Novartis Investigative Site, Seoul, Korea, 05505, Korea, Republic of\|Novartis Investigative Site, Seoul, Korea, 06351, Korea, Republic of\|Novartis Investigative Site, Seoul, Seocho Gu, 06591, Korea, Republic of\|Novartis Investigative Site, Utrecht, The Netherlands, 3508 GA, Netherlands\|Novartis Investigative Site, Amsterdam, 1066 CX, Netherlands\|Novartis Investigative Site, Rotterdam, 3075 EA, Netherlands\|Novartis Investigative Site, Oslo, NO-0424, Norway\|Novartis Investigative Site, Singapore, 169610, Singapore\|Novartis Investigative Site, Granada, Andalucia, 18014, Spain\|Novartis Investigative Site, Oviedo, Asturias, 33006, Spain\|Novartis Investigative Site, Barcelona, Catalunya, 08035, Spain\|Novartis Investigative Site, Madrid, 28046, Spain\|Novartis Investigative Site, Zaragoza, 50009, Spain\|Novartis Investigative Site, Tainan, Taiwan ROC, 70403, Taiwan\|Novartis Investigative Site, Taipei, Taiwan ROC, 10041, Taiwan\|Novartis Investigative Site, Songkhla, Hat Yai, 90110, Thailand Less <<
NCT04460729	Non-small Cell Lung Carcinoma ... More >>(NSCLC) Less <<	PHASE2	WITHDRAWN	2023-11-17	-
NCT04677595	Non-Small Cell Lung Cancer (NS... More >>CLC) Less <<	PHASE2	ACTIVE_NOT_RECRUITING	2025-12-31	Novartis Investigative Site, X... More >>iamen, Fujian, 361001, China\|Novartis Investigative Site, Foshan, Guangdong, 528000, China\|Novartis Investigative Site, Guang Zhou, Guangdong, 510120, China\|Novartis Investigative Site, Guangzhou, Guangdong, 510080, China\|Novartis Investigative Site, Guangzhou, Guangdong, 510515, China\|Novartis Investigative Site, Harbin, Heilongjiang, 150081, China\|Novartis Investigative Site, Zhengzhou, Henan, 450003, China\|Novartis Investigative Site, Wuhan, Hubei, 430022, China\|Novartis Investigative Site, Shenyang, Liaoning, 110011, China\|Novartis Investigative Site, Jinan, Shandong, 250117, China\|Novartis Investigative Site, Shanghai, Shanghai, 200032, China\|Novartis Investigative Site, Shanghai, Shanghai, 200433, China\|Novartis Investigative Site, Chengdu, Sichuan, 610041, China\|Novartis Investigative Site, Kunming, Yunnan, 650106, China\|Novartis Investigative Site, Hangzhou, Zhejiang, 310022, China\|Novartis Investigative Site, Beijing, 100036, China\|Novartis Investigative Site, Tianjin, 300052, China Less <<

{[proInfo.proName]}

CAS No.: 1029712-80-8

{[proInfo.proName]}

CAS No.: 1029712-80-8

Product Citations

Alternative Products

Product Details of Capmatinib

Safety of Capmatinib

Related Pathways of Capmatinib

Isoform Comparison

Biological Activity

Protocol

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	2.42mL 0.48mL 0.24mL	12.12mL 2.42mL 1.21mL	24.25mL 4.85mL 2.42mL
Dissolving Methods	Animal experiment The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed